Trials / Withdrawn
WithdrawnNCT06286046
A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy
A Phase 2, Open-label, Multicenter Study of Mitapivat in Subjects With Sickle Cell Disease and Nephropathy (RESIST)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Agios Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the effect of mitapivat on albumin creatinine ratio (ACR) response in participants with sickle cell disease (SCD) and nephropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mitapivat | Tablets |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2027-05-01
- Completion
- 2028-12-01
- First posted
- 2024-02-29
- Last updated
- 2026-04-03
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06286046. Inclusion in this directory is not an endorsement.